Eli Lilly & Company to supply its human insulin active pharmaceutical ingredient (API) to IABL at a reduced cost in order to facilitate the manufacturing of insulin in Bangladesh.
Boehringer Ingelheim teamed up with 3T Biosciences to identify and create cutting-edge cancer treatments to meet the significant unmet patient needs. Further, the collaboration will combine the industry-leading 3T-TRACE (T-Cell Receptor Antigen and Cross-Reactivity Engine) discovery platform from 3T Biosciences with Boehringer Ingelheim's two-pronged research approach combining cancer cell-directed and immune cell-targeting compounds.
Author Credits: Radhika Gupta, Shivam Bhutani
Report ID: 3846
Published Date: Aug 08, 2023
Report Format: PDF, PPT
Frequently Asked Questions (FAQ)
Increasing incidence of neuroendocrine cancer is the major factor driving the market growth.
The market size of neuroendocrine tumor treatment is anticipated to attain a CAGR of ~12% over the forecast period, i.e., 2023 â€“ 2035.
The major players in the market are BoehringerIngelheim International GmbH, Hutchison MediPharma Limited, AVEO Oncology, Pfizer, Inc., IpsenPharma, Tarveda Therapeutics, Progenics Pharmaceuticals, Novartis AG, Eli Lilly & Company, Ipsen Pharma, and others.
The hospitals segment is anticipated to garner the largest market size by the end of 2035 and display significant growth opportunities.
The market in the North America region is projected to hold the largest market share by the end of 2035 and provide more business opportunities in the future.